We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-15.27%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$72.6M
AUM Growth
+$36.2M
Cap. Flow
+$39.4M
Cap. Flow %
54.35%
Top 10 Hldgs %
38.26%
Holding
170
New
94
Increased
8
Reduced
36
Closed
17

Sector Composition

Rank Sector Weight
1 Energy 48.57%
2 Healthcare 38.33%
3 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ALDR
101
DELISTED
Alder Biopharmaceuticals
ALDR
$178K 0.25%
7,273
-455
-6% -$10.5K
ALNY icon
102
Alnylam Pharmaceuticals
ALNY
$36.3B
$176K 0.24%
+2,799
New +$186K
SGMO
103
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$176K 0.24%
29,061
-1,786
-6% -$10.7K
ARAV
104
DELISTED
Aravive, Inc. Common Stock
ARAV
$176K 0.24%
+3,652
New +$194K
KYNB
105
Kyntra Bio
KYNB
$28.5M
$175K 0.24%
+329
New +$164K
MCRB icon
106
Seres Therapeutics
MCRB
$48M
$175K 0.24%
+329
New +$172K
CNCE
107
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$173K 0.24%
12,664
-792
-6% -$11.4K
QURE icon
108
uniQure
QURE
$2.68B
$168K 0.23%
+14,182
New +$209K
MRTX
109
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$168K 0.23%
+7,828
New +$175K
IOVA icon
110
Iovance Biotherapeutics
IOVA
$2.23B
$164K 0.23%
+32,352
New +$177K
IMGN
111
DELISTED
Immunogen Inc
IMGN
$164K 0.23%
+19,257
New +$163K
GERN icon
112
Geron
GERN
$911M
$163K 0.22%
55,936
-3,500
-6% -$10.5K
KPTI icon
113
Karyopharm Therapeutics
KPTI
$168M
$160K 0.22%
+1,195
New +$132K
NVAX icon
114
Novavax
NVAX
$1.23B
$159K 0.22%
1,539
-97
-6% -$10.4K
MGNX icon
115
MacroGenics
MGNX
$235M
$157K 0.22%
8,385
-526
-6% -$10K
CYTK icon
116
Cytokinetics
CYTK
$11B
$156K 0.21%
+22,124
New +$162K
ONCE
117
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$155K 0.21%
+5,251
New +$166K
RARE icon
118
Ultragenyx Pharmaceutical
RARE
$2.65B
$152K 0.21%
+2,404
New +$157K
XLRN
119
DELISTED
Acceleron Pharma
XLRN
$152K 0.21%
+5,756
New +$167K
PRTA icon
120
Prothena Corp
PRTA
$458M
$150K 0.21%
+3,650
New +$143K
SAGE
121
DELISTED
Sage Therapeutics
SAGE
$148K 0.2%
+4,602
New +$162K
ISEE
122
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$148K 0.2%
3,510
-225
-6% -$11.5K
CASC
123
DELISTED
Cascadian Therapeutics, Inc.
CASC
$148K 0.2%
19,445
-1,209
-6% -$9.31K
ACGN
124
DELISTED
Aceragen Inc
ACGN
$147K 0.2%
+545
New +$146K
SIOX
125
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$144K 0.2%
+1,572
New +$168K

Similar funds

Virtus ETF Advisers's Q1 2016 Portfolio in Review

As of Q1 2016, Virtus ETF Advisers held 170 positions worth $72.6M, up 99% from $36.4M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Virtus ETF Advisers deployed $39.4M of net new capital in Q1 2016, opening 94 new positions and adding to 8 existing holdings. Its largest new stake was Energy Transfer Partners L.p.: 127,467 shares worth $4.12M.

By sector, the portfolio is most concentrated in Energy at 49% of assets, up from 27% a quarter earlier, followed by Healthcare and Utilities.

On the sell side, the largest reduction was Spectra Energy Corp Wi, an estimated $258K trimmed.

  • Virtus ETF Advisers's largest Q1 2016 buy was Energy Transfer Partners L.p.: 127,467 shares worth $4.12M.
  • Virtus ETF Advisers added most to Buckeye Partners, L.P. in Q1 2016, an estimated $1.73M increase.
  • Virtus ETF Advisers's biggest Q1 2016 reduction was Spectra Energy Corp Wi, cutting an estimated $258K.
  • Virtus ETF Advisers fully exited Aegerion Pharmaceuticals in Q1 2016, selling an estimated $656K.
  • Virtus ETF Advisers's ten largest holdings make up 38% of its $72.6M portfolio in Q1 2016.
  • Virtus ETF Advisers opened 94 new positions and closed 17 in Q1 2016.
  • Virtus ETF Advisers's portfolio value rose 99% quarter-over-quarter to $72.6M.

Based on Virtus ETF Advisers's 13F filing for Q1 2016, filed 16 May 2016.